

Match Overview

1	Crossref 59 words Xiaoran Chu, Wei Du, Min Xu, Zhenggao Xie, Jun Zhu, Ying Zhu, Fang Chen. "Intravitreal conbercept combined with	2%
2	Crossref 48 words Longli Zhang, Yifeng Ke, Wei Wang, Xueying Shi, Kaiwen Hei, Xiaorong Li. "The efficacy of conbercept or ranibizum	2%
3	Internet 43 words crawled on 19-Aug-2020 worldwidescience.org	1%
4	Internet 33 words crawled on 24-Sep-2020 www.hindawi.com	1%
5	Internet 26 words crawled on 18-Oct-2017 pure.uva.nl	1%
6	Internet 24 words crawled on 02-Jun-2014 www.empire.ca	1%
7	Internet 24 words crawled on 02-Aug-2019 www.dovepress.com	1%
8	Internet 19 words crawled on 09-Oct-2020 www.wjgnet.com	1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58483

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Three-year follow-up¹³ of coats disease treated with conbercept and 532-nm laser photocoagulation

Jiang L *et al.* Conbercept and laser for coats disease

Li Jiang, Bo Qin, Xiao-Ling Luo, He Cao, Ting-Ming Deng, Ming-Ming Yang, Ting Meng, Hui-Qin Yang

Abstract

BACKGROUND

Coats disease is an idiopathic exudative outer retinopathy caused by abnormal retinal vascular development.



ALL

IMAGES

VIDEOS

3,660 Results

Any time ▾

Advanced Coats' disease treated with intravitreal ...

<https://www.sciencedirect.com/science/article/pii/S2451993620301481>

1. Introduction. Coats' disease, first described in 1908, is characterized by peripheral vascular ectasia, aneurysms, and exudation. 2 Historically, the main treatment included repetitive laser photocoagulation to areas of nonperfusion and telangiectasias. 3 Recent studies have demonstrated upregulation of VEGF in patients with Coats' disease, 4 and this has prompted interest in ...

Author: Nimesh A. Patel, Audina M. Berrocal, ... Publish Year: 2020

Coats disease: An overview of classification, management ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552590>

Apr 29, 2019 - Stage of disease Treatment Follow up Results; Venkatesh et al. 2008: Case series: 2: 14, 16 y: 2: Bevacizumab 1.25 mg, laser photocoagulation: 6 m: Improvement in VA Resolution of subfoveal serous detachment and exudative detachment No recurrence: Lin et al. 2010: Case series: 3: 10 y, 6 m, 12 y: 2B-3B: Bevacizumab 2.5 mg, laser ...

Cited by: 1

Author: Mittika Sen, Carol L Shields, Santosh G ...

Publish Year: 2019

Intravitreal bevacizumab injections combined with laser ...

<https://europepmc.org/article/MED/26631136> ▾

All patients were treated at baseline using intravitreal bevacizumab injections combined with laser photocoagulation. Follow-up treatment was performed as necessary. RESULTS: The mean age of the subjects was 40.3 years, and the mean follow-up period was 24.8 months.

Cited by: 8

Author: Saemi Park, Han Joo Cho, Dong Won Le...

Publish Year: 2016

Coats' disease: A Lifetime Disease

<https://www.researchgate.net/publication/7175899...>

Aggressive treatment of Coats' disease with cryotherapy with or without 532 nm laser, before retinal detachment, is likely to stabilize vision and decrease the risk of future total retinal detachment.

The efficacy of conbercept or ranibizumab intravitreal ...

<https://link.springer.com/article/10.1007/s00417-018-3949-1> ▾

Mar 16, 2018 - The current treatment approaches for Coats' disease by intravitreal injection of anti-

Treatment of stage 3 Coats’ disease by endolaser ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483254>

Multiple modalities have been employed to treat **Coats’ disease**, including diathermy, **laser photocoagulation**, cryotherapy, subretinal fluid drainage, scleral buckling surgery, pars plana vitrectomy, and intravitreal anti-vascular endothelial growth factor (VEGF) therapy [6–8]. **Treatment** is aimed at destroying abnormal vasculature and ...

Cited by: 10 **Author:** Xuan Cai, Peiquan Zhao, Qi Zhang, Haiying ...
Publish Year: 2015

Advanced Coats’ disease treated with intravitreal ...

<https://www.sciencedirect.com/science/article/pii/S2451993620301481>

Sep 01, 2020 · 1. Introduction. **Coats’ disease**, first described in 1908, 1 is characterized by peripheral vascular ectasia, aneurysms, and exudation. 2 Historically, the main **treatment** included repetitive **laser photocoagulation** to areas of nonperfusion and telangiectasias. 3 Recent studies have demonstrated upregulation of VEGF in patients with **Coats’ disease**, 4 and this has prompted interest in ...

Author: Nimesh A. Patel, Audina M. Berrocal, Ti... **Publish Year:** 2020

Intravitreal Conbercept Injection with and without Grid ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061960>

To evaluate the efficacy of intravitreal **conbercept** (IVC) plus modified grid **laser photocoagulation** (MGP) versus IVC alone for **treatment** of diffuse diabetic macular edema (DDME). Methods. In this retrospective study, 51 DDME patients were **treated** with either IVC alone (IVC group) or IVC plus MGP (combined group) with 12 months of **follow-up**.

Cited by: 5 **Author:** Yule Xu, Ao Rong, Yanlong Bi, Wei Xu
Publish Year: 2016

The efficacy of conbercept or ranibizumab intravitreal ...

<https://link.springer.com/article/10.1007/s00417-018-3949-1> ▾

Mar 16, 2018 · The current **treatment** approaches for **Coats’ disease** by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or **conbercept**) combined with **laser** therapy were evaluated for the efficacy during the **treatment**. The medical records of 28 patients diagnosed with **Coats’ disease** followed by the **treatment** with intravitreal injection of anti-VEGF agents ...

Cited by: 10 **Author:** Longli Zhang, Yifeng Ke, Wei Wang, Xueyin...
Publish Year: 2018

Coats' disease: A Lifetime Disease - ResearchGate

<https://www.researchgate.net/publication/7175899...>

Aggressive **treatment** of **Coats’ disease** with cryotherapy with or without 532 nm **laser**, before retinal detachment, is likely to stabilize vision and decrease the risk of future total retinal detachment.

Intravitreal bevacizumab injections combined with laser ...

<https://europepmc.org/article/MED/26631136> ▾

All patients were **treated** at baseline using intravitreal bevacizumab injections combined with **laser photocoagulation**. **Follow-up treatment** was performed as necessary. RESULTS:The mean age of the subjects was 40.3 years, and the mean **follow-up** period was 24.8 months.

Factors Predictive of Subretinal Fluid Resolution in Coats ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727930>

Aug 09, 2019 · Stage 1 **disease** was often asymptomatic and was observed or prophylactically **treated** with **laser photocoagulation**, whereas stages with increasing amounts of retinal exudation or subretinal fluid (SRF) were associated with decreased visual acuity, requiring **treatment** with modalities such as **laser photocoagulation**, cryotherapy, or a combination of ...

Coats' syndrome: Long term follow up | Request PDF

<https://www.researchgate.net/publication/51356991...>

Eleven eyes with retinal telangiectasia and exudation were **treated** with argon **laser photocoagulation** alone or **photocoagulation** associated with cryotherapy; the mean **follow up** was 32.5 (range,17-41 ...

Clinical efficacy evaluation of treatment of different ...

<https://www.spandidos-publications.com/etm/17/3/1563> ▾

The solid **laser** therapeutic instrument (Iridex, Mountain View, CA, USA) with the frequency multiplication of 532 nm was used for grid **photocoagulation** in the macular region. ... in the 6-month **follow-up**, ... Shi X, Hei K and Li X: The efficacy of **conbercept** or ranibizumab intravitreal injection combined with **laser** therapy for **Coats’ disease** ...

Anti-VEGF treatment for myopic choroid neovascularization ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26170626>

More notably, Bennett and Yee68 reported that a young female patient with myopic CNV who had been refractive to **laser photocoagulation**, PDT, and intravitreal TA, and was **treated** with IVP injections for 5 weeks, had ETDRS VA improvement from counting fingers to 20/40 in the right eye. The results suggest that, at least in this case, IVP appears ...

Clinical efficacy evaluation of treatment of different ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364225>

Comparison of BCVA in **follow-up**. In 1, 3 and 6 months of **follow-up**, BCVA was evaluated in trunk occlusion group, branch occlusion group, hemi-occlusion group **treated** with ranibizumab or ranibizumab combined with argon ion **laser**. *P<0.05 and **P<0.01 vs. the control. BCVA, best corrected visual acuity.

Advanded Coats' disease. Management with repetitive ...

<https://www.researchgate.net/publication/51393095...>

Aggressive **treatment** of **Coats’ disease** with cryotherapy with or without 532 nm **laser**, before retinal detachment, is likely to stabilize vision and decrease the risk of future total retinal detachment.

Efficacy and Safety Outcomes of Intravitreal Dexamethasone ...

<https://www.hindawi.com/journals/joph/2020/9131908> ▾

<i>Purpose</i>. To evaluate the efficacy and safety outcomes of dexamethasone intravitreal implant in patients with Stage 3A **Coats’ disease**. <i>Methods</i>. A consecutive case series of adult **Coats’ disease** managed with or without intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, California, USA) injection was retrospectively evaluated. The medical records of all ...

Clinical efficacy evaluation of treatment of different ...

<https://europepmc.org/article/PMC/PMC6364225> ▾

Dec 21, 2018 · Comparison of the remission rate of macular edema in **follow-up** (%). In 6 months of **follow-up**, the remission rate of macular edema was evaluated in trunk occlusion group, branch occlusion group, hemi-occlusion group **treated** with ranibizumab or ranibizumab combined with argon ion **laser**. **P<0.01 vs. the control.

[ALL](#)[IMAGES](#)[VIDEOS](#)[MAPS](#)[NEWS](#)[SHOPPING](#)

5,920 Results

Any time ▾

[Treatment of stage 3 Coats' disease by endolaser ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483254>

Multiple modalities have been employed to treat **Coats' disease**, including diathermy, **laser photocoagulation**, cryotherapy, subretinal fluid drainage, scleral buckling surgery, pars plana vitrectomy, and intravitreal anti-vascular endothelial growth factor (VEGF) therapy [6–8]. **Treatment** is aimed at destroying abnormal vasculature and ...

Cited by: 10**Author:** Xuan Cai, Peiquan Zhao, Qi Zhang, Haiyi...**Publish Year:** 2015

[Advanced Coats' disease treated with intravitreal ...](#)

<https://www.sciencedirect.com/science/article/pii/S2451993620301481>

Sep 01, 2020 · 1. Introduction. **Coats' disease**, first described in 1908, 1 is characterized by peripheral vascular ectasia, aneurysms, and exudation. 2 Historically, the main **treatment** included repetitive **laser photocoagulation** to areas of nonperfusion and telangiectasias. 3 Recent studies have demonstrated upregulation of VEGF in patients with **Coats' disease**, 4 and this has prompted interest in ...

Author: Nimesh A. Patel, Audina M. Berrocal, ...**Publish Year:** 2020

[Factors Predictive of Subretinal Fluid Resolution in Coats ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727930>

Aug 09, 2019 · Stage 1 **disease** was often asymptomatic and was observed or prophylactically **treated** with **laser photocoagulation**, whereas stages with increasing amounts of retinal exudation or subretinal fluid (SRF) were associated with decreased visual acuity, requiring **treatment** with modalities such as **laser photocoagulation**, cryotherapy, or a combination of ...

Cited by: 1**Author:** Chloe T.L. Khoo, Lauren A. Dalvin, Li-Ann...**Publish Year:** 2019

[Coats' disease: A Lifetime Disease - ResearchGate](#)

<https://www.researchgate.net/publication/7175899...>

Aggressive **treatment of Coats' disease** with cryotherapy with or without **532 nm laser**, before retinal detachment, is likely to stabilize vision and decrease the risk of future total retinal detachment.

[The efficacy of conbercept or ranibizumab intravitreal](#)